Nuvalent Inc Cl A (NUVL) Stock Price, Quote & News

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 357 7000

Website: www.nuvalent.com

Address:

One Broadway, 14th Floor, Cambridge, United States

BearTamerTrading Jan. 11 at 11:56 PM

On Watch for JPM Week: Part 1 $JNJ – Johnson & Johnson – presenting at the conference on Jan 12, 2026. $ACAD – Acadia Pharmaceuticals – presenting on Jan 13, 2026. $ONC – BeOne Medicines Ltd. – presenting on Jan 13, 2026. $NUVL – Nuvalent, Inc. – presenting on Jan 13, 2026. $ARWR – Arrowhead Pharmaceuticals – scheduled to present on Jan 12, 2026.

0 · Reply

KirRoyalTrader Jan. 10 at 4:51 AM

$NUVL - Weekly A cup-with-handle pattern forming right at all-time highs.

0 · Reply

Anonymcq Jan. 8 at 2:28 AM

$NUVL overbought. Good data = capital raise. I don’t short often, but this one I’ll bet against!

0 · Reply

JuggernautRaider Jan. 6 at 7:34 PM

Buy $NUVB Hold $PFE Sell $NUVL 💎 🤔

0 · Reply

JFais Dec. 31 at 1:21 PM

one hurdle for $BHVN in Kv7 is $XENE has many more years' worth of patient data (huge gap in the race) Kind of reminds me of $NUVL in ROS1 chasing $NUVB in frontline ROS1 NSCLC (hard to overcome the 1st mover advantage, needs several more years to put out something comparable)

1 · Reply

InnovationInv Dec. 27 at 9:26 AM

$NUVL Trading dynamics suggest reliability now matters more than momentum bursts. Competitive advantages must begin to appear in core metrics. Predictability would attract a deeper institutional audience. Future returns depend more on reliability than ambition.

0 · Reply

IN0V8 Dec. 26 at 4:43 PM

$NUVL Buy Truist Securities initiates coverage with buy rating; PT $140

0 · Reply

OfficialStocktwitsUser Dec. 25 at 1:36 PM

$NUVL RSI: 47.16, MACD: 0.8531 Vol: 2.32, MA20: 105.65, MA50: 101.01 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

justiceforb_85 Dec. 23 at 5:16 AM

$NUVL likely best-in-class for ROS1/ALK NSCLC. Look forward to data for HER2 agent (NVL-330).

0 · Reply

Sw1ngb0t Dec. 19 at 10:21 PM

$HCTI $EOSE $PTGX $ONDS $NUVL

0 · Reply

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:30 AM EST - 2 days ago

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

Dec 22, 2025, 6:30 AM EST - 23 days ago

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 4:01 PM EST - 5 weeks ago

Nuvalent Appoints Ron Squarer to Board of Directors

Nov 26, 2025, 6:30 AM EST - 7 weeks ago

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 4:01 PM EST - 7 weeks ago

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

Nov 19, 2025, 4:19 PM EST - 2 months ago

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Nov 18, 2025, 11:50 PM EST - 2 months ago

Nuvalent Announces Pricing of Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 2 months ago

Nuvalent Announces Public Offering of Common Stock

Nov 17, 2025, 3:47 PM EST - 2 months ago

Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript

Nov 17, 2025, 1:03 PM EST - 2 months ago

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

Nov 17, 2025, 6:30 AM EST - 2 months ago

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

Nov 14, 2025, 4:01 PM EST - 2 months ago

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

Nov 4, 2025, 9:28 PM EST - 2 months ago

Nuvalent: Interesting Product, But Aggressive Valuation

Nov 4, 2025, 5:12 PM EST - 2 months ago

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Oct 30, 2025, 6:30 AM EDT - 2 months ago

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Oct 18, 2025, 6:00 AM EDT - 3 months ago

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Oct 13, 2025, 12:53 PM EDT - 3 months ago

Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 1, 2025, 6:22 PM EDT - 3 months ago

Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript

Sep 24, 2025, 6:30 AM EDT - 4 months ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 7, 2025, 4:45 AM EDT - 4 months ago

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Aug 28, 2025, 6:30 AM EDT - 4 months ago

Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Aug 13, 2025, 1:06 PM EDT - 5 months ago

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

Aug 7, 2025, 6:30 AM EDT - 5 months ago

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:30 AM EDT - 6 months ago

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

Jun 24, 2025, 6:30 AM EDT - 7 months ago

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Jun 23, 2025, 4:30 PM EDT - 7 months ago

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Jun 18, 2025, 4:30 PM EDT - 7 months ago

Nuvalent Appoints Christy Oliger to Board of Directors

May 8, 2025, 7:31 AM EDT - 8 months ago

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 1:09 PM EDT - 9 months ago

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Apr 23, 2025, 10:28 AM EDT - 9 months ago

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Apr 1, 2025, 6:30 AM EDT - 10 months ago

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 5:24 PM EDT - 10 months ago

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Feb 28, 2025, 6:30 AM EST - 11 months ago

Nuvalent to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 6:30 AM EST - 11 months ago

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 6:30 AM EST - 1 year ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Jan 10, 2025, 1:22 PM EST - 1 year ago

Nuvalent: A Logical Acquisition Target

Dec 19, 2024, 6:30 AM EST - 1 year ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 6:30 AM EST - 1 year ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nov 26, 2024, 6:52 AM EST - 1 year ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 6:30 AM EST - 1 year ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Sep 23, 2024, 12:34 PM EDT - 1 year ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Sep 16, 2024, 10:23 PM EDT - 1 year ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Sep 16, 2024, 1:44 PM EDT - 1 year ago

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Sep 16, 2024, 11:18 AM EDT - 1 year ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 14, 2024, 5:00 AM EDT - 1 year ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Sep 13, 2024, 9:53 AM EDT - 1 year ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Sep 9, 2024, 6:30 AM EDT - 1 year ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

BearTamerTrading Jan. 11 at 11:56 PM

0 · Reply

KirRoyalTrader Jan. 10 at 4:51 AM

$NUVL - Weekly A cup-with-handle pattern forming right at all-time highs.

0 · Reply

Anonymcq Jan. 8 at 2:28 AM

$NUVL overbought. Good data = capital raise. I don’t short often, but this one I’ll bet against!

0 · Reply

JuggernautRaider Jan. 6 at 7:34 PM

Buy $NUVB Hold $PFE Sell $NUVL 💎 🤔

0 · Reply

JFais Dec. 31 at 1:21 PM

1 · Reply

InnovationInv Dec. 27 at 9:26 AM

0 · Reply

IN0V8 Dec. 26 at 4:43 PM

$NUVL Buy Truist Securities initiates coverage with buy rating; PT $140

0 · Reply

OfficialStocktwitsUser Dec. 25 at 1:36 PM

0 · Reply

justiceforb_85 Dec. 23 at 5:16 AM

$NUVL likely best-in-class for ROS1/ALK NSCLC. Look forward to data for HER2 agent (NVL-330).

0 · Reply

Sw1ngb0t Dec. 19 at 10:21 PM

$HCTI $EOSE $PTGX $ONDS $NUVL

0 · Reply

JarvisFlow Dec. 19 at 4:21 PM

JP Morgan has updated their rating for Nuvalent ( $NUVL ) to Overweight with a price target of 145.

0 · Reply

Sw1ngb0t Dec. 16 at 3:11 AM

$NUVL getting ready to move

0 · Reply

Sw1ngb0t Dec. 9 at 4:41 AM

$NUVL $ERAS $DKS $CRDF $ALGT

0 · Reply

Sw1ngb0t Dec. 8 at 9:37 PM

piddly guaranteed targets: $INV $6.32+ $NUVB $10.24+ $NUVL $125.02+ $CCCC $2.91+ $ERAS $3.72+

0 · Reply

justiceforb_85 Dec. 8 at 8:22 PM

$NUVL adding. Look forward to company advancing their ALK and ROS1 inhibitor to front line space.

0 · Reply

BillionerOfKing Dec. 5 at 12:02 AM

$NUVL Current Stock Price: $106.84 Contracts to trade: $105 NUVL Dec 19 2025 Call Entry: $2.70 Exit: $3.79 ROI: 40% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BEATOFtheMARKET Dec. 3 at 10:39 AM

$NUVB $NUVL $NVDA $NVDG $NVDL Undeniable Accuracy 🔥 Only if you too blind too see 🔥 Cycle Trading Signal plugged into AI 🔥 lists 🔥

0 · Reply

inflect1on Dec. 2 at 7:10 AM

$NUVL on watch rest of week

0 · Reply

Night_Owl_Biotech Nov. 30 at 2:04 AM

The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B. NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B. This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years. $XBI $IBB

0 · Reply

Sw1ngb0t Nov. 26 at 10:16 PM

$CYPH $PGEN $NUVB $NUVL $LBRT

0 · Reply

JarvisFlow Nov. 24 at 6:00 PM

Truist Securities has updated their rating for Nuvalent ( $NUVL ) to Buy with a price target of 140.

0 · Reply

Sw1ngb0t Nov. 23 at 9:22 PM

$CYPH $URGN $NUVL on their way

0 · Reply

Market Cap	7.36B
Revenue (ttm)	0.00
Net Income (ttm)	-260.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	574,500
Avg Vol	629,218
Day's Range	N/A - N/A
Shares Out	72.71M
Stochastic %K	95%
Beta	1.32
Analysts	Strong Sell
Price Target	$141.71